Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IRTC.O
IRTC.O logo

IRTC.O Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
122.660
Open
120.730
VWAP
120.60
Vol
510.45K
Mkt Cap
3.87B
Low
119.500
Amount
61.56M
EV/EBITDA(TTM)
--
Total Shares
32.32M
EV
3.96B
EV/OCF(TTM)
48.98
P/S(TTM)
5.16
iRhythm Holdings, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. It designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using its Zio Systems. The Zio Monitor System is a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for over 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
Show More

Events Timeline

(ET)
2026-02-20
10:50:00
iRhythm Receives DOJ Investigative Demand
select
2026-02-19 (ET)
2026-02-19
16:30:00
iRhythm Expects Revenue of $870M to $880M for 2026
select
2026-02-19
16:30:00
iRhythm Reports Q4 Revenue of $208.89M, Beating Consensus
select

News

seekingalpha
9.5
02-20seekingalpha
iRhythm Holdings Reports Strong Q4 2025 Earnings Growth
  • Significant Revenue Growth: iRhythm reported Q4 2025 revenue of $208.9 million, reflecting a 27.1% year-over-year increase, with full-year revenue reaching $747.1 million, a 26.2% growth, underscoring strong performance in cardiology and primary care, thereby solidifying market position.
  • Profitability Breakthrough: The company achieved a net income of $5.6 million for the fourth quarter, translating to $0.17 per diluted share, marking the first positive quarterly net income in its history, with adjusted EBITDA at $34.3 million or 16.4% of revenue, indicating a significant improvement in profitability.
  • International Market Expansion: iRhythm has commercialized in the U.K., select EU markets, and Japan, achieving its largest quarterly volume ever in the U.K., highlighting rapid growth potential in international markets that will further drive future revenue growth.
  • Optimistic Outlook: The company expects 2026 revenue to range between $870 million and $880 million, representing a 16% to 18% year-over-year growth, while adjusted EBITDA margins are projected to expand to 11.5% to 12.5%, reflecting confidence in sustained growth and profitability.
seekingalpha
9.5
02-19seekingalpha
iRhythm Technologies Exceeds 2025 Earnings Expectations
  • Significant Revenue Growth: iRhythm Technologies reported a revenue of $747.1 million for 2025, reflecting a 26.2% year-over-year increase primarily driven by heightened demand for Zio services, indicating strong growth potential in the cardiac monitoring market.
  • Improved Gross Margin: The gross profit for 2025 was $527.3 million, with a gross margin of 70.6%, up from 68.9% in 2024, showcasing enhancements in scale and operational efficiencies that contributed to lower unit service costs.
  • Reduced Net Loss: The net loss for 2025 was $44.6 million, translating to a diluted loss of $1.39 per share, a significant improvement from the net loss of $113.3 million and diluted loss of $3.63 per share in 2024, reflecting progress towards profitability.
  • Optimistic 2026 Guidance: iRhythm anticipates revenue between $870 million and $880 million for 2026, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued volume-led growth and disciplined investment in innovation and market expansion.
seekingalpha
9.5
02-18seekingalpha
iRhythm Technologies Set to Announce Q4 Earnings
  • Earnings Announcement: iRhythm Technologies is set to release its Q4 2023 earnings on February 19th after market close, with consensus EPS estimates at $0.06, reflecting a 250% year-over-year increase, and revenue estimates at $202.61 million, indicating a 23.3% year-over-year growth, showcasing the company's robust growth potential.
  • Performance Beat Record: Over the past two years, iRhythm has beaten EPS estimates 50% of the time and has achieved a 100% beat rate on revenue estimates, underscoring the company's strong reputation among market analysts and consistent performance.
  • Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced seven upward revisions and one downward change, reflecting mixed market sentiment regarding the company's future performance, which could impact investor confidence.
  • Future Growth Outlook: iRhythm anticipates exceeding its revenue guidance for 2025 and forecasts up to 18% growth in 2026, demonstrating the company's confidence in future market opportunities and a proactive growth strategy.
PRnewswire
7.0
01-29PRnewswire
Investigation into iRhythm Technologies' Corporate Governance Breaches
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
  • Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
  • Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
  • Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
Globenewswire
7.0
01-28Globenewswire
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
  • Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
  • Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
  • Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
  • No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
PRnewswire
7.0
01-21PRnewswire
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
  • Investigation Background: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
  • Product Misrepresentation: Insiders at iRhythm repeatedly touted the Zio AT as an innovative product with significant growth potential, while it was actually a real-time monitor intended for high-risk patients, which investors viewed favorably due to its premium pricing.
  • Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, potentially causing financial losses for investors, prompting shareholders to contact legal counsel promptly to protect their rights.
  • Legal Fee Commitment: Kuehn Law commits to covering all case costs and does not charge its investor clients, encouraging shareholders to get involved to uphold the integrity and fairness of financial markets.
Wall Street analysts forecast IRTC.O stock price to rise
13 Analyst Rating
Wall Street analysts forecast IRTC.O stock price to rise
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
205.00
Averages
222.00
High
244.00
Current: 0.000
sliders
Low
205.00
Averages
222.00
High
244.00
Citi
Joanne Wuensch
Buy
downgrade
$242 -> $214
AI Analysis
2026-03-11
New
Reason
Citi
Joanne Wuensch
Price Target
$242 -> $214
AI Analysis
2026-03-11
New
downgrade
Buy
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on iRhythm to $214 from $242 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain "healthy" despite the recent volatility, the analyst tells investors in a research note. Citi's top picks are iRhythm and Medtronic.
Truist
Richard Newitter
Buy
maintain
$215 -> $200
2026-02-23
Reason
Truist
Richard Newitter
Price Target
$215 -> $200
2026-02-23
maintain
Buy
Reason
Truist analyst Richard Newitter lowered the firm's price target on iRhythm to $200 from $215 but keeps a Buy rating on the shares. The company delivered Q4 revenue as preannounced as the beat was fueled by another strong ZioAT quarter and progress with innovative channel partners, the analyst tells investors in a research note. The firm adds however that peers have seen some multiple compresson, which underlies the slight multiple and price target reduction.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IRTC.O
Unlock Now

Valuation Metrics

The current forward P/E ratio for iRhythm Holdings, Inc (IRTC.O) is -352.98, compared to its 5-year average forward P/E of -66.99. For a more detailed relative valuation and DCF analysis to assess iRhythm Holdings, Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-66.99
Current PE
-352.98
Overvalued PE
10.70
Undervalued PE
-144.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
206.52
Current EV/EBITDA
65.37
Overvalued EV/EBITDA
1120.85
Undervalued EV/EBITDA
-707.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
6.52
Current PS
6.81
Overvalued PS
8.47
Undervalued PS
4.57

Financials

AI Analysis
Annual
Quarterly

Whales Holding IRTC.O

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is iRhythm Holdings, Inc (IRTC.O) stock price today?

The current price of IRTC.O is 119.64 USD — it has decreased -0.74

What is iRhythm Holdings, Inc (IRTC.O)'s business?

iRhythm Holdings, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. It designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using its Zio Systems. The Zio Monitor System is a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for over 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

What is the price predicton of IRTC.O Stock?

Wall Street analysts forecast IRTC.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC.O is222.00 USD with a low forecast of 205.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is iRhythm Holdings, Inc (IRTC.O)'s revenue for the last quarter?

iRhythm Holdings, Inc revenue for the last quarter amounts to 208.89M USD, increased 27.12

What is iRhythm Holdings, Inc (IRTC.O)'s earnings per share (EPS) for the last quarter?

iRhythm Holdings, Inc. EPS for the last quarter amounts to 0.17 USD, decreased -525.00

How many employees does iRhythm Holdings, Inc (IRTC.O). have?

iRhythm Holdings, Inc (IRTC.O) has 2400 emplpoyees as of March 12 2026.

What is iRhythm Holdings, Inc (IRTC.O) market cap?

Today IRTC.O has the market capitalization of 3.87B USD.